The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma
Open accessAbstract
Background & Aims In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have been associated with outcome, there is no method to predict recurrence based on combined clinical, pathology, and genomic data (from tumor and cirrhotic tissue). We evaluated gene expression signatures associated with outcome in a large cohort of patients with early-stage (BCLC 0/A), single-nodule HCC and heterogeneity of signatures within tumor tissues. Methods We assessed 287 HCC patients undergoing resection and tested genome-wide expression platforms using tumor (n=287) and adjacent non-tumor, cirrhotic tissue (n=226). We evaluated gene expression signatures with reported prognostic ability generated from tumor or cirrhotic tissue in 18 and 4 reports, respectively. In 15 additional patients, we profiled samples from the center and periphery of the tumor, to determine stability of signatures. Data analysis included Cox modeling and random survival forests to identify independent predictors of tumor recurrence. Results Gene expression signatures that were associated with aggressive HCC were clustered, as well as those associated with tumors of progenitor cell origin and those from non-tumor, adjacent, cirrhotic tissues. On multivariate analysis, the tumor-associated signature “G3-proliferation” (hazard ratio [HR]=1.75, P=0.003) and an adjacent “poor-survival” signature (HR=1.74, P=0.004) were independent predictors of HCC recurrence, along with satellites (HR=1.66, P=0.04). Samples from different sites in the same tumor nodule were reproducibly classified. Conclusions We developed a composite prognostic model for HCC recurrence, based on gene expression patterns in tumor and adjacent tissues. These signatures predict early and overall recurrence in patients with HCC, and complement findings from clinical and pathology analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Self-citationDesign and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationImamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Self-citationTranscriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationA novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Self-citationYe, Q.-H., Qin, L.-X., Forgues, M., He, P., Kim, J. W., Peng, A. C., Simon, R., Li, Y., Robles, A. I., Chen, Y., et al. (2003) · Nature Medicine · doi:10.1038/nm843 · Cited by 850
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Self-citationFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationEpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Enabling personalized cancer medicine through analysis of gene-expression patterns
van 't Veer, L. J., & Bernards, R. (2008) · Nature · doi:10.1038/nature06915 · Cited by 554
Iizuka, N., Oka, M., Yamada-Okabe, H., Nishida, M., Maeda, Y., Mori, N., Takao, T., Tamesa, T., Tangoku, A., Tabuchi, H., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12775-4 · Cited by 511
Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., Goga, A., Balakrishnan, A., Semeraro, M., Gresh, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.002 · Cited by 509
Kaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Hoshida, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015543 · Cited by 382
Self-citationClinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
Komuta, M., Spee, B., Borght, S. V., De Vos, R., Verslype, C., Aerts, R., Yano, H., Suzuki, T., Matsuda, M., Fujii, H., et al. (2008) · Hepatology · doi:10.1002/hep.22238 · Cited by 363
Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008) · Hepatology · doi:10.1002/hep.22283 · Cited by 332
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
Komuta, M., Borght, S. V., Kojiro, M., Aerts, R., & Roskams, T. (2007) · Cited by 301
Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
Consistency of random survival forests
Ishwaran, H., & Kogalur, U. B. (2010) · Statistics & Probability Letters · doi:10.1016/j.spl.2010.02.020 · Cited by 271
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma
Woo, H. G., Lee, J.-H., Yoon, J.-H., Kim, C. Y., Lee, H.-S., Jang, J. J., Yi, N.-J., Suh, K.-S., Lee, K. U., Park, E. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2823 · Cited by 190
Gene-expression signature of vascular invasion in hepatocellular carcinoma
Mínguez, B., Hoshida, Y., Villanueva, A., Toffanin, S., Cabellos, L., Thung, S., Mandeli, J., Sia, D., April, C., Fan, J.-B., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.034 · Cited by 159
Self-citationWoo, H. G., Park, E. S., Cheon, J. H., Kim, J. H., Lee, J., Park, B. J., Kim, W. K., Park, S. C., Chung, Y. J., Kim, B. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1473 · Cited by 157
Progenitor‐derived hepatocellular carcinoma model in the rat†
Andersen, J. B., Loi, R., Perra, A., Factor, V. M., Ledda‐Columbano, G. M., Columbano, A., & Thorgeirsson, S. S. (2009) · Hepatology · doi:10.1002/hep.23488 · Cited by 152
New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
Villanueva, A., Hoshida, Y., Toffanin, S., Lachenmayer, A., Alsinet, C., Savić, R., Cornellà, H., & Llovet, J. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1811 · Cited by 125
Self-citationMolecular-based prediction of early recurrence in hepatocellular carcinoma
Kurokawa, Y., Matoba, R., Takemasa, I., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Sakon, M., Ueno, N., Oba, S., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.04.031 · Cited by 119
Okamoto, M., Utsunomiya, T., Wakiyama, S., Hashimoto, M., Fukuzawa, K., Ezaki, T., Hanai, T., Inoue, H., & Mori, M. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.07.018 · Cited by 91
Molecular prediction of early recurrence after resection of hepatocellular carcinoma
Yoshioka, S., Takemasa, I., Nagano, H., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.019 · Cited by 60
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“None of the biomarkers tested so far fulfil these criteria in HCC, but four just require external validation by independent groups: gene signatures or biomarkers from the tumor (EpCAM signature, G3-proliferation subclass, and miR-26a) [77,135,136] and adjacent tissue (poor-survival signature) [137].”
BackgroundVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Self-citationForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationHepatocellular carcinoma: clinical frontiers and perspectives
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014) · Gut · doi:10.1136/gutjnl-2013-306627 · Cited by 1,364
Self-citation
Metadata
- Authors
- Villanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberzon, A., Kobayashi, M., Kumada, H., Thung, S. N., Bruix, J., Newell, P., April, C., Fan, J., Roayaie, S., Mazzaferro, V., Schwartz, M. E., & Llovet, J. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 140
- Issue
- 5
- Pages
- 1501-1512.e2
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2046257690
- Cited by
- 447
- References
- 42
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.